As time passes, we get ever closer to the date that Zogenix releases its new hydrocodone formulation, Zohydro. As announced in January 2012, this new formulation of pain medication will contain five times as much of the pain-killing drug hydrocodone but none of the acetaminophen that the earlier formulations contained. These formulations were known as Lortab, Vicodin, Lorcet, and many other names. But in continuous use as when a person suffers from chronic pain, the acetaminophen presents risks of liver toxicity and damage.
On the other hand, hydrocodone is a very commonly abused drug. As it is addictive, it sends many people who have abused it to drug rehabs for recovery.
Despite the concerns of regulators and those who care for those who become addicted, Zohydro is in clinical trials and it set to hit the pain-relief market in 2013.
There are three other pharmaceutical companies who are developing new all-hydrocodone formulas: Teva Pharmaceuticals in Israel, Purdue Pharma that also manufactures OxyContin, and Egalet in Denmark. These other companies are working on formulations that contain deterrents to abusing or tampering with the pills, for example, crushing or dissolving them. The Zogenix formulation does not contain any deterrents.
Will Narconon Centers See More People Needing Drug Rehab?
Hydrocodone is addictive, but the large dosage of acetaminophen that now is included in current formulations is not. This means that anyone taking or abusing the upcoming Zohydro is going to be getting a higher dose of addictive material with every dose. Will this mean that more people are going to be seeking help at Narconon drug and alcohol rehabilitation centers across the US?
Already, as many as half the new arrivals at some Narconon centers are seeking help for addiction to pain relievers and other prescription drugs. In 2009, it was estimated that more than 23 million Americans had abused hydrocodone at some point. More than 86,000 needed assistance at an emergency room after they had abused this drug. As an opiate, hydrocodone suppresses a person’s respiration. As it is frequently abused along with alcohol which also suppresses respiration, this can present a threat of death when both drugs work together stop a person’s breathing.
Lasting Recovery is an Essential Part of Curtailing This Epidemic
According to reports from the Substance Abuse and Mental Health Services Administration (SAMHSA), about one in three people admitted to addiction treatment in 2010 were being admitted for the first time. The other two were going back to rehab because they did not manage to stay sober. Effective rehabilitation that results in lasting sobriety is needed to fight this epidemic of substance abuse and addiction.
But many drug rehabs do not profess to eliminate addiction. Instead, they quote success rates of somewhere around 20% and explain that relapse is part of recovery. So the family may not be surprised when their loved one begins to abuse drugs once again. The success of the Narconon drug recovery program means that families do not need to experience this “revolving door” of addiction treatment.
Instead, Narconon centers monitor their graduates for a two year period and find that 70% of them stay sober after they get home. This means that even if the threat of addiction stays high because of these new hydrocodone formulations coming on the market, families can find effective help for their loved ones who may become trapped after abusing pain relievers for a short period – or a long one.
Call the Narconon International office to get more information about the Narconon drug rehabilitation program.